Ajith Sivadasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ajith Sivadasan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Vivek Mathew
Department of Neurological Sciences, Christian Medical College, Tamil Nadu, Vellore, India
9 shared publications- Aditya Vijayakrishnan Nair
Department of Neurological Sciences, Christian Medical College, Vellore, Tamil Nadu, India
5 shared publications Sanjith Aaron
Department of Neurological Sciences, Christian Medical College, Tamil Nadu, Vellore, India
4 shared publicationsAditya Nair
Department of Neurological Sciences, Christian Medical College, Tamil Nadu, Vellore, India
3 shared publicationsAditya Vijayakrishnan Nair
3 shared publications- Angel Miraclin Thirugnanakumar
Department of Neurological Sciences, Christian Medical College, Vellore, Tamil Nadu, India
3 shared publications
Latest Publications
- 8 October 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (11) , 5461-5468
Idiopathic Intracranial Hypertension Presenting With Pulsatile Tinnitus: A Retrospective Audiovestibular Case Series
- 8 October 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (11) , 5461-5468
Idiopathic Intracranial Hypertension Presenting With Pulsatile Tinnitus: A Retrospective Audiovestibular Case Series
- Open Access
- 5 December 2025
- Published by Elsevier in EBioMedicine
- Vol. 123, 106055
Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy
- 5 December 2025
- Published by Elsevier in EBioMedicine
- Vol. 123, 106055
Open AccessTopical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy
- Open Access
- 18 August 2025
- Published by Elsevier in Neuroimmunology Reports
- Vol. 8
“When HIV meets MG: Is immune reconstitution in the mix?”
- 18 August 2025
- Published by Elsevier in Neuroimmunology Reports
- Vol. 8
Open Access“When HIV meets MG: Is immune reconstitution in the mix?”
- Open Access
- 25 March 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (2) , 299-301
Broadening the Phenotypic Range: KCNJ2 Variant Linked to Isolated Periodic Paralysis with Fixed Myopathy
An abstract is unavailable. This article is available as a PDF only.
- 25 March 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (2) , 299-301
Open AccessBroadening the Phenotypic Range: KCNJ2 Variant Linked to Isolated Periodic Paralysis with Fixed Myopathy
An abstract is unavailable. This article is available as a PDF only.
- 22 March 2025
- Published by BMJ in Practical Neurology
- Vol. 25 (5) , 448-451
Catastrophic antiphospholipid antibody syndrome provoked by eltrombopag
Antiphospholipid antibody syndrome (APS) may rarely present with isolated thrombocytopenia that may be diagnosed and treated as immune thrombocytopenic purpura. A 32-year-old woman was given eltrombopag (a thrombopoietin receptor agonist) to treat presumed immune thrombocytopenic purpura. She developed catastrophic APS, with multiple ischaemic infarcts, microvascular coronary thrombosis and digital gangrene. She improved after stopping eltrombopag and starting immunotherapy (corticosteroids, intravenous immunoglobulin and rituximab) but was left with significant neurological morbidity.
- 22 March 2025
- Published by BMJ in Practical Neurology
- Vol. 25 (5) , 448-451
Catastrophic antiphospholipid antibody syndrome provoked by eltrombopag
Antiphospholipid antibody syndrome (APS) may rarely present with isolated thrombocytopenia that may be diagnosed and treated as immune thrombocytopenic purpura. A 32-year-old woman was given eltrombopag (a thrombopoietin receptor agonist) to treat presumed immune thrombocytopenic purpura. She developed catastrophic APS, with multiple ischaemic infarcts, microvascular coronary thrombosis and digital gangrene. She improved after stopping eltrombopag and starting immunotherapy (corticosteroids, intravenous immunoglobulin and rituximab) but was left with significant neurological morbidity.
- 30 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre
To find out if Rituximab (RTX) is effective in “treatment naive” idiopathic inflammatory myopathies (IIM), and whether there could be differential treatment responses between the “treatment naive” and treatment “refractory” IIM. Data obtained from a prospectively maintained database comprising patients with IIM treated with rituximab. Patient details were obtained at baseline, 3-months, 6-months intervals, and subsequent follow up visits. Treatment response was categorised as improved, worsening, or stable based on manual muscle testing (MMT8) scores, patient global and physician global improvement (PtGA and PGA) for skin and joint symptoms improvement and spirometry at 6 months. The time to clinical improvement and remission were noted and survival analysis curves were constructed. 60 patients with IIM (including 18 with anti-SRP myopathy) were included, out of which 33 who received RTX were treatment naïve. The remaining 27 were started on rituximab for refractory myopathy. Mean age was 39 years (SD12.58) in “treatment-naive” group and 43 years (SD 12.12) in “refractory” group. At 6 months of follow up, 48/55 (87%) patients showed response, 31/31 (100%) in “treatment-naive” and 17/24 (70%) in “refractory” cases, p 0.006*. In refractory group, 7 (29%) had stable disease. The mean changes in MMT8 were significantly more in the “treatment-naive” treatment group (13.41(SD 7.31) compared with “refractory” IIM 8.33 (SD 7.92) (p= 0.017*). Majority of patients were able to reduce dose below 5 mg/day before 6 months. No major adverse events were reported over the median follow-up of 24 (IQR 36) months. Rituximab is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.
- 30 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre
To find out if Rituximab (RTX) is effective in “treatment naive” idiopathic inflammatory myopathies (IIM), and whether there could be differential treatment responses between the “treatment naive” and treatment “refractory” IIM. Data obtained from a prospectively maintained database comprising patients with IIM treated with rituximab. Patient details were obtained at baseline, 3-months, 6-months intervals, and subsequent follow up visits. Treatment response was categorised as improved, worsening, or stable based on manual muscle testing (MMT8) scores, patient global and physician global improvement (PtGA and PGA) for skin and joint symptoms improvement and spirometry at 6 months. The time to clinical improvement and remission were noted and survival analysis curves were constructed. 60 patients with IIM (including 18 with anti-SRP myopathy) were included, out of which 33 who received RTX were treatment naïve. The remaining 27 were started on rituximab for refractory myopathy. Mean age was 39 years (SD12.58) in “treatment-naive” group and 43 years (SD 12.12) in “refractory” group. At 6 months of follow up, 48/55 (87%) patients showed response, 31/31 (100%) in “treatment-naive” and 17/24 (70%) in “refractory” cases, p 0.006*. In refractory group, 7 (29%) had stable disease. The mean changes in MMT8 were significantly more in the “treatment-naive” treatment group (13.41(SD 7.31) compared with “refractory” IIM 8.33 (SD 7.92) (p= 0.017*). Majority of patients were able to reduce dose below 5 mg/day before 6 months. No major adverse events were reported over the median follow-up of 24 (IQR 36) months. Rituximab is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 122-131
“De Novo” Hypercapnic Respiratory Failure Unmasking Neuromuscular Disorders: Experiences From a Tertiary Care Center and Review of Literature
Objectives: Neuromuscular disorders could have respiratory involvement early or late into illness. Rarely, patients may present with a hypercapnic respiratory failure (with minimal motor signs) unmasking an underlying disease. There are hardly any studies which have addressed the spectrum and challenges involved in management of this subset, especially in the real-world scenario. Methods: A retrospective study comprising consecutive patients hospitalized with hypercapnic respiratory failure as the sole/dominant manifestation. The clinical–electrophysiological spectrum, phrenic conductions, diaphragm thickness, and outcomes were analyzed. Results: Twenty-seven patients were included, the mean age was 47.29 (SD 15.22) years, and the median duration of respiratory symptoms was 2 months (interquartile range [IQR] 1–4). Orthopnea was present in 23 patients (85.2%) and encephalopathy in 8 patients (29.6%). Phrenic nerve latencies and amplitudes were abnormal in 83.3% and 95.6%, respectively. Abnormal diaphragm thickness was noted in 78.5%. Based on a comprehensive electrophysiological strategy and paraclinical tests, an etiology was established in all. Reversible etiologies were identified in 17 patients (62.9%). These included myasthenia gravis (anti-AChR and MuSK), inflammatory myopathy, riboflavin transporter deficiency neuronopathy, Pompe disease, bilateral phrenic neuritis, and thyrotoxicosis. Respiratory onset motor neuron disease was diagnosed in 8 patients (29.6%). Despite diaphragmatic involvement, a functional respiratory recovery was noted at discharge (45%) and last follow-up (60%). Predictors for good outcomes included female sex, normal nerve conductions, and recent-onset respiratory symptoms. Discussion: A good functional recovery was noted in most of the patients including respiratory onset motor neuron disease. A systematic algorithmic approach helps in proper triaging, early diagnosis, and treatment. Clinical and electrodiagnostic challenges and observations from a tertiary care referral center are discussed.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 122-131
“De Novo” Hypercapnic Respiratory Failure Unmasking Neuromuscular Disorders: Experiences From a Tertiary Care Center and Review of Literature
Objectives: Neuromuscular disorders could have respiratory involvement early or late into illness. Rarely, patients may present with a hypercapnic respiratory failure (with minimal motor signs) unmasking an underlying disease. There are hardly any studies which have addressed the spectrum and challenges involved in management of this subset, especially in the real-world scenario. Methods: A retrospective study comprising consecutive patients hospitalized with hypercapnic respiratory failure as the sole/dominant manifestation. The clinical–electrophysiological spectrum, phrenic conductions, diaphragm thickness, and outcomes were analyzed. Results: Twenty-seven patients were included, the mean age was 47.29 (SD 15.22) years, and the median duration of respiratory symptoms was 2 months (interquartile range [IQR] 1–4). Orthopnea was present in 23 patients (85.2%) and encephalopathy in 8 patients (29.6%). Phrenic nerve latencies and amplitudes were abnormal in 83.3% and 95.6%, respectively. Abnormal diaphragm thickness was noted in 78.5%. Based on a comprehensive electrophysiological strategy and paraclinical tests, an etiology was established in all. Reversible etiologies were identified in 17 patients (62.9%). These included myasthenia gravis (anti-AChR and MuSK), inflammatory myopathy, riboflavin transporter deficiency neuronopathy, Pompe disease, bilateral phrenic neuritis, and thyrotoxicosis. Respiratory onset motor neuron disease was diagnosed in 8 patients (29.6%). Despite diaphragmatic involvement, a functional respiratory recovery was noted at discharge (45%) and last follow-up (60%). Predictors for good outcomes included female sex, normal nerve conductions, and recent-onset respiratory symptoms. Discussion: A good functional recovery was noted in most of the patients including respiratory onset motor neuron disease. A systematic algorithmic approach helps in proper triaging, early diagnosis, and treatment. Clinical and electrodiagnostic challenges and observations from a tertiary care referral center are discussed.
- Open Access
- 28 February 2024
- Published by Wiley in Academic Emergency Medicine
- Vol. 31 (4) , 386-397
Peripheral nervous system and neuromuscular disorders in the emergency department: A review
Introduction: Acute presentations and emergencies in neuromuscular disorders (NMDs) often challenge clinical acumen. The objective of this review is to refine the reader's approach to history taking, clinical localization and early diagnosis, as well as emergency management of neuromuscular emergencies.Methods: An extensive literature search was performed to identify relevant studies. We prioritized meta‐analysis, systematic reviews, and position statements where possible to inform any recommendations.Summary: The spectrum of clinical presentations and etiologies ranges from neurotoxic envenomation or infection to autoimmune disease such as Guillain–Barré Syndrome (GBS) and myasthenia gravis (MG). Delayed diagnosis is not uncommon when presentations occur “de novo,” respiratory failure is dominant or isolated, or in the case of atypical scenarios such as GBS variants, severe autonomic dysfunction, or rhabdomyolysis. Diseases of the central nervous system, systemic and musculoskeletal disorders can mimic presentations in neuromuscular disorders.Conclusions: Fortunately, early diagnosis and management can improve prognosis. This article provides a comprehensive review of acute presentations in neuromuscular disorders relevant for the emergency physician.
- 28 February 2024
- Published by Wiley in Academic Emergency Medicine
- Vol. 31 (4) , 386-397
Open AccessPeripheral nervous system and neuromuscular disorders in the emergency department: A review
Introduction: Acute presentations and emergencies in neuromuscular disorders (NMDs) often challenge clinical acumen. The objective of this review is to refine the reader's approach to history taking, clinical localization and early diagnosis, as well as emergency management of neuromuscular emergencies.Methods: An extensive literature search was performed to identify relevant studies. We prioritized meta‐analysis, systematic reviews, and position statements where possible to inform any recommendations.Summary: The spectrum of clinical presentations and etiologies ranges from neurotoxic envenomation or infection to autoimmune disease such as Guillain–Barré Syndrome (GBS) and myasthenia gravis (MG). Delayed diagnosis is not uncommon when presentations occur “de novo,” respiratory failure is dominant or isolated, or in the case of atypical scenarios such as GBS variants, severe autonomic dysfunction, or rhabdomyolysis. Diseases of the central nervous system, systemic and musculoskeletal disorders can mimic presentations in neuromuscular disorders.Conclusions: Fortunately, early diagnosis and management can improve prognosis. This article provides a comprehensive review of acute presentations in neuromuscular disorders relevant for the emergency physician.
- Open Access
- 23 June 2023
- Published by BMJ in BMJ Neurology Open
- Vol. 5 (1) , e000414
Opsoclonus myoclonus ataxia syndrome, ovarian teratoma and anti-NMDAR antibody: an ‘unresolved’ mystery
Background Opsoclonus–myoclonus–ataxia syndrome (OMAS) is characterised by the combination of opsoclonus and arrhythmic action myoclonus with axial ataxia and dysarthria. In adults, a majority are paraneoplastic secondary to solid organ tumours and could harbour antibodies against intracellular epitopes; however, certain proportions have detectable antibodies to various neuronal cell surface antigens. Anti-N-methyl-D-aspartate (NMDAR) antibodies and ovarian teratomas have been implicated in OMAS. Methods Report of two cases and review of literature. Results Two middle-aged women presented with subacute-onset, rapidly progressive OMAS and behavioural changes consistent with psychosis. The first patient had detectable antibodies to NMDAR in the cerebrospinal fluid (CSF) alone. Evaluation for ovarian teratoma was negative. The second patient had no detectable antibodies in serum or CSF; however, she had an underlying ovarian teratoma. Patient A was treated with pulse steroids, therapeutic plasma exchange (TPE) followed by bortezomib (BOR) and dexamethasone, while patient B was treated with steroids, TPE followed by surgical resection of ovarian teratoma. Both patients had favourable outcomes and were asymptomatic at the 6 monthly follow-up. Conclusions With coexistent neuropsychiatric manifestations, OMAS can be considered a distinct entity of autoimmune encephalitis, pathogenesis being immune activation against known/unknown neuronal cell surface antigens. The observation of absence of anti-NMDAR antibody in patients with teratoma-associated OMAS and vice versa is intriguing. Further research on the potential role of ovarian teratoma in evoking neuronal autoimmunity and its targets is required. The management challenge in both cases including the potential use of BOR has been highlighted.
- 23 June 2023
- Published by BMJ in BMJ Neurology Open
- Vol. 5 (1) , e000414
Open AccessOpsoclonus myoclonus ataxia syndrome, ovarian teratoma and anti-NMDAR antibody: an ‘unresolved’ mystery
Background Opsoclonus–myoclonus–ataxia syndrome (OMAS) is characterised by the combination of opsoclonus and arrhythmic action myoclonus with axial ataxia and dysarthria. In adults, a majority are paraneoplastic secondary to solid organ tumours and could harbour antibodies against intracellular epitopes; however, certain proportions have detectable antibodies to various neuronal cell surface antigens. Anti-N-methyl-D-aspartate (NMDAR) antibodies and ovarian teratomas have been implicated in OMAS. Methods Report of two cases and review of literature. Results Two middle-aged women presented with subacute-onset, rapidly progressive OMAS and behavioural changes consistent with psychosis. The first patient had detectable antibodies to NMDAR in the cerebrospinal fluid (CSF) alone. Evaluation for ovarian teratoma was negative. The second patient had no detectable antibodies in serum or CSF; however, she had an underlying ovarian teratoma. Patient A was treated with pulse steroids, therapeutic plasma exchange (TPE) followed by bortezomib (BOR) and dexamethasone, while patient B was treated with steroids, TPE followed by surgical resection of ovarian teratoma. Both patients had favourable outcomes and were asymptomatic at the 6 monthly follow-up. Conclusions With coexistent neuropsychiatric manifestations, OMAS can be considered a distinct entity of autoimmune encephalitis, pathogenesis being immune activation against known/unknown neuronal cell surface antigens. The observation of absence of anti-NMDAR antibody in patients with teratoma-associated OMAS and vice versa is intriguing. Further research on the potential role of ovarian teratoma in evoking neuronal autoimmunity and its targets is required. The management challenge in both cases including the potential use of BOR has been highlighted.